公开(公告)号：WO2004017908A2

公开(公告)日：2004-03-04

申请号：PCT/US0326317

申请日：2003-08-21

Applicant: TAKEDA CHEMICAL INDUSTRIES LTD ,  YASUMA TSUNEO ,  MORI AKIRA ,  KAWASE MASAHIRO ,  KIMURA HIROYUKI ,  YOSHIDA MASATO ,  GYORKOS ALBERT CHARLES ,  PRATT SCOTT ALAN ,  CORRETTE CHRISTOPHER PETER

Inventor： YASUMA TSUNEO ,  MORI AKIRA ,  KAWASE MASAHIRO ,  KIMURA HIROYUKI ,  YOSHIDA MASATO ,  GYORKOS ALBERT CHARLES ,  PRATT SCOTT ALAN ,  CORRETTE CHRISTOPHER PETER

IPC: A61K31/00 ,  A61P19/08 ,  C07D487/04 ,  A61K

CPC classification number: C07D487/04

Abstract: There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7- membered ring; ring B is an optionally substituted 5- to 7- membered heterocyclic ring; X is CR , CR R , N or NR ; X is N or NR ; Y is C, CR or N, Z is CR , CR R , N or NR ; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and --- is a single bond or a double bond; R , R , R , R , R , R , R and R are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7- membered ring; Q is C, CR or N; R , R ,R , R and R are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X , R , R , Y and X in formula (II) and (III) as before.

Abstract translation: 提供了包含式（I）化合物的钙受体调节剂：其中环A是任选取代的5-至7-元环; 环B是任选取代的5-至7-元杂环; X 1是CR 1，CR 1 R 2，N或NR 13; X 2是N或NR 3; Y是C，CR 4或N，Z是CR 5，CR 5 R 6，N或NR 7; Ar是任选取代的环状基团; R为H，任选取代的烃基等; ---是单键或双键; R 1，R 2，R 3，R 4，R 5，R 6，R 7和R 13独立地为H，任选取代的烃基; 或其盐或其前药。 式（II）和（III）的化合物：其中环A是任选取代的5-至7-元环; Q为C，CR 5或N; R 8，R 9，R 10，R 11和R 12独立地是H，任选取代的烃基等，或其盐。 还如前所述地在式（II）和（III）中指定X 1，R 3，R 1，Y和X 3。

公开(公告)号：WO1993013086A1

公开(公告)日：1993-07-08

申请号：PCT/JP1992001661

申请日：1992-12-18

Applicant: TAISHO PHARMACEUTICAL CO., LTD. ,  SATO, Masakazu ,  KAWASE, Masahiro ,  MANAKA, Akira ,  KAWASHIMA, Yutaka ,  HATAYAMA, Katsuo

Inventor： TAISHO PHARMACEUTICAL CO., LTD.

IPC: C07D295/08

CPC classification number: C07D239/42 ,  C07D213/74 ,  C07D295/088 ,  C07D295/112 ,  C07D295/185

Abstract: To provide a compound with a potent ACAT inhibiting activity. An anilide derivative represented by general formula (I) and a salt thereof, wherein R and R may be the same or different from each other and each represents C1-C4 alkyl; n represents 0, 1 or 2; A represents C1-C14 alkylene or -CH2CO-; and Ar represents phenyl or benzyl each of which may be substituted by halogen, nitro, C1-C4 alkyl, C1-C4 alkoxy, C2-C5 alkanoyl or trifluoromethyl, or pyridyl or pyrimidyl each of which may be substituted by halogen or trifluoromethyl.

Abstract translation: 以提供具有有效的ACAT抑制活性的化合物。 由通式（I）表示的苯胺衍生物及其盐，其中R 1和R 2可以相同或不同，各自表示C1-C4烷基; n表示0,1或2; A表示C1-C14亚烷基或-CH2CO-; 并且Ar表示可以被卤素，硝基，C 1 -C 4烷基，C 1 -C 4烷氧基，C 2 -C 5烷酰基或三氟甲基取代的苯基或苄基，或各自可被卤素或三氟甲基取代的吡啶基或嘧啶基。

公开(公告)号：WO2004017908A3

公开(公告)日：2004-03-04

申请号：PCT/US2003/026317

申请日：2003-08-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  YASUMA, Tsuneo ,  MORI, Akira ,  KAWASE, Masahiro ,  KIMURA, Hiroyuki ,  YOSHIDA, Masato ,  GYORKOS, Albert, Charles ,  PRATT, Scott, Alan ,  CORRETTE, Christopher, Peter

Inventor： YASUMA, Tsuneo ,  MORI, Akira ,  KAWASE, Masahiro ,  KIMURA, Hiroyuki ,  YOSHIDA, Masato ,  GYORKOS, Albert, Charles ,  PRATT, Scott, Alan ,  CORRETTE, Christopher, Peter

IPC: C07D221/04

Abstract: There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7- membered ring; ring B is an optionally substituted 5- to 7- membered heterocyclic ring; X 1 is CR 1 , CR 1 R 2 , N or NR 13 ; X 2 is N or NR 3 ; Y is C, CR 4 or N, Z is CR 5 , CR 5 R 6 , N or NR 7 ; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and --- is a single bond or a double bond; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 13 are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7- membered ring; Q is C, CR 5 or N; R 8 , R 9 ,R 10 , R 11 and R 12 are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X 1 , R 3 , R 1 , Y and X 3 in formula (II) and (III) as before.

公开(公告)号：WO0174823A3

公开(公告)日：2002-02-07

申请号：PCT/JP0102614

申请日：2001-03-29

Applicant: TAKEDA CHEMICAL INDUSTRIES LTD ,  YASUMA TSUNEO ,  MORI AKIRA ,  KAWASE MASAHIRO ,  TAKIZAWA MASAYUKI ,  MIKI SHOKYO ,  TAKEDA MITSUHIRO

Inventor： YASUMA TSUNEO ,  MORI AKIRA ,  KAWASE MASAHIRO ,  TAKIZAWA MASAYUKI ,  MIKI SHOKYO ,  TAKEDA MITSUHIRO

IPC: A61P19/00 ,  C07D495/04 ,  C07D498/04 ,  A61K31/424

CPC classification number: C07D495/04

Abstract: There is disclosed novel fused thiophene derivatives as prophylactic and therapeutic drugs for bone or articular diseases, industrially advantageous processes for production thereof, and novel production intermediates. Said fused thiophene derivatives are represented by the general formula (I) wherein R is an optionally substituted hydrocarbon, heterocyclic, sulfinyl, sulfonyl, hydroxyl, thiol or amino group,; R is cyano, formyl, thioformyl, etc.; ring A is any of formulae (a), (b) or (c) (wherein R is hydrogen or an optionally substituted hydrocarbon, heterocyclic, hydroxyl, amino, sulfonyl or acyl; R is hydrogen, halogen, optionally subsituted hydrocarbon group, optionally subsituted heterocyclic group etc.; and ring B represents an optionally substituted 5- to 7-membered hydrocarbon ring.

Abstract translation: 公开了新的稠合噻吩衍生物作为骨或关节疾病的预防和治疗药物，其工业上有利的生产方法和新的生产中间体。 所述稠合噻吩衍生物由通式（I）表示，其中R 1是任选取代的烃，杂环，亚磺酰基，磺酰基，羟基，硫醇或氨基; R 2是氰基，甲酰基，硫代甲酰基等; 环A是式（a），（b）或（c）中的任一个（其中R 3是氢或任选取代的烃，杂环，羟基，氨基，磺酰基或酰基; R 14是氢，卤素， 任选取代的烃基，任选取代的杂环基等;并且环B表示任选取代的5至7元烃环。

公开(公告)号：WO1990012664A1

公开(公告)日：1990-11-01

申请号：PCT/JP1990000517

申请日：1990-04-20

Applicant: KABUSHIKI KAISHA KOBE SEIKO SHO ,  ITASHIKI, Masakazu ,  FUJIWARA, Koichi ,  MURAKAMI, Kenji ,  KAWASE, Masahiro ,  ICHIDA, Yutaka ,  WADA, Sakae ,  SHIGENAGA, Mikio ,  HOSOYA, Seiichi ,  MARUKAWA, Nobuaki

Inventor： KABUSHIKI KAISHA KOBE SEIKO SHO

IPC: B21B37/00

CPC classification number: B21B37/005 ,  B21B1/18 ,  B21B2015/0014 ,  B21B2275/06

Abstract: This invention relates to a wire rod dividing method in wire rod mill which method is used for producing a plurality of wire coils from one slab by dividing the wire rod produced by wire rod mill on a rolling line. This equipment includes flying shears (4) for cutting the wire rod (3), disposed between rolling mill lines (2, 5) consisting of a plurality of rolling mills (ST7 SIMILAR ST11) and after the wire rod (3) is cut by the flying shears (4), the rolling speed by the rolling mill (ST8) upstream the cutting position of the wire rod (3) or by the rolling mill (ST9) on the downstream side is controlled in order to provide a relative speed difference between the leading wire rod (3a) downstream the cutting position and the trailing wire rod (3b) upstream the cutting position. A suitable gap is secured between the leading and trailing wires (3a) and (3b), and the cut wire coils are separated reliably from one another even when the finish rolling line is used on the downstream side.

Abstract translation: 线材磨机中的线材分割方法技术领域本发明涉及线材轧机中的线材分割方法，该方法用于通过将线材轧机生产的线材在轧制线上分割而从一个板坯制造多根线材。 该设备包括用于切割线材（3）的飞剪（4），设置在由多个轧机（ST7类型ST11）组成的轧制线（2,5）之间，并且在线材（3）被 飞行剪（4），控制在线材（3）的切割位置上游的轧机（ST8）或下游侧的轧机（ST9）的轧制速度，以提供相对速度差 在切割位置下游的前导线（3a）和在切割位置上游的后线圈（3b）之间。 即使在下游侧使用精轧线，也能够在前后导丝（3a）和（3b）之间形成合适的间隙，切断线圈彼此可靠地分离。

公开(公告)号：JP2002222262A

公开(公告)日：2002-08-09

申请号：JP2001017315

申请日：2001-01-25

Applicant: KAWASE MASAHIRO ,  SHIMAZU S D KK

Inventor： KAWASE MASAHIRO ,  NAKADA TAKAYUKI

IPC: G06Q50/22 ,  G06F17/60

Abstract: PROBLEM TO BE SOLVED: To quantitatively evaluate the bodily development degree and the mental development degree of an infant and the properness of a child care environment. SOLUTION: In this electronic child care support system, since an evaluation part 1C and an evaluation part 2C respectively calculate the bodily development degree, the mental developmental degree and the properness of the child care environment in numerical forms of total scores based on statuses of replies to questions regarding the bodily development degree, the mental development degree and the properness of the child care environment stored in correspondence to prescribed age of the infant in a computer 1, or a data storing part 1A or a data storing part 2A of a computer 2 and evaluation scores precedently provided per each question to appropriate a status of a reply, evaluation to be the foundation of child care guidance is highly objective quantitative evaluation and a difference in child care guidance contents can be avoided.